Biorepository and Bioinformatics

Biorepository and Bioinformatics

Antibodies

Nuclea has developed an extensive biorepository of highly-characterized clinical specimens, including biopsy tissue and sera, representing a number of human diseases, especially cancer and inflammatory disease. Nuclea has collected and organized the underlying data linked to each specimen including gene and protein expression data, into linked databases that include extensive HIPAA compliant demographic and clinical patient data.

Nuclea's proprietary Tissue MicroArray ("TMA") technology allows raw gene sequence information to be profiled on thousands of tissue samples, thereby identifying the role of these genes in specific human disease. Results obtained from TMAs are linked to data on known gene markers in Nuclea's proprietary database, enabling the searching and linking of new genomic sequence data to the actual biological function and medical importance, thereby providing rapid gene target profiling. Nuclea's platform technology overcomes the limitations of pure database platforms as the drug discovery process can advance seamlessly from analysis of cells on TMAs to the analysis of data, simultaneously integrating new data.

Nuclea also has a proprietary algorithm that allows it to analyze its extensive clinical and expression data to generate molecular marker profiles for known disease markers, to further characterize the clinical specimens, and to build its gene signature profile database. “Gene signature profile database” refers to a database architecture where tissues and other clinical specimens are linked to their related data, including epidemiology, both clinical and molecular (gene and protein expression) data, thereby achieving an integrated platform of biological and data resources used to fully-characterize the role of certain genes and proteins in human disease.

[  back to top  ]